Company intelligence / Profile preview

Simcere Pharmaceutical Group

Ownership: Public · 2096
Employees: ~6412
Development stage: Commercial

Overview

Simcere has developed and launched 3 category I innovative pharmaceuticals in China. Recent clinical developments include SIM0500 (Phase 1 for multiple myeloma), SIM0508 (received clinical trial approval), and XIANNUOXIN (approved in China). The company has over 150 clinical trials.

Therapeutic areas: CardiovascularRheumatologyImmunologyDermatologyOncologyNeurologyInfectious Diseases
Modalities: Small moleculesmonoclonal antibodiestrispecific antibodies
Industry: Biotech

Drug pipeline

89 assets

quadrivalent split influenza virus vaccine

Approved

88 more assets in the full pipeline.

Request access →

Partnerships

AbbVieConnect BiopharmaLynk PharmaceuticalsAlmirallDaiichi SankyoShenzhen TargetRxMass General Brigham

Beyond the preview

Go deeper on Simcere Pharmaceutical Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Simcere Pharmaceutical Group.

Explore the full profile